mardi 21 mars 2017

Onco Actu du 21 mars 2017

4.9 Dép., diag. & prono. - Sein

Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy [Genomic Health]

5. Traitements

What PCSK9 Is Telling Us About Drug Discovery [In the Pipeline]

Popular Prostate Cancer Therapy Is Short, Intense and Unproved [NY Times]

5.10 Traitements - Essais

Lilly gets positive abemaciclib phase 3 data, plots 2017 NDA [Fierce Biotech]

Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival [Lilly]

Laggard Lilly says its CDK 4/6 drug abemaciclib scored in PhIII, while rivals at Novartis, Pfizer sharpen their knives [EndPoints]

Lilly's breast cancer drug combination succeeds key study [Reuters]

5.12 Immunothérapies

Tethered nanoparticles make tumor cells more vulnerable [MIT News]

5.12.1 Immunothérapies - partenariats

Bristol-Myers Squibb, CytomX pen expanded $3.6B biobucks research deal [Fierce Biotech]

First Trial Underway, CytomX Gets $200M More In Expanded Bristol Pact [Xconomy]

Bristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody™ Therapeutics for the Treatment of Cancer and Other Diseases [BMS]

CTLA-4 bound for the clinic, Bristol-Myers hands CytomX $200M to kick off an expanded discovery pact [EndPoints]

5.12.2 Immunothérapies - CAR-T

Researchers Use CRISPR Gene-Editing Tool to Help Turn Immune Cells against Tumors [NCI]

5.2 Pharma

Losing Nemo: Array pulls skin cancer NDA for binimetinib [Fierce Biotech]

Array walks back its FDA pitch on binimetinib, derailing plans for commercial launch [EndPoints]

5.4 Traitements - Economie

A Better Balance Between Accelerated Access And High-Priced New Drugs: A New Conditional Approval Option [Health Affairs Blog]

Health secretary backs 'easier' medicines access system [BBC News]

5.9 AACR

Elizabeth M. Jaffee, MD, Named American Association for Cancer Research President-Elect 2017-2018 [AACR]

6. Lutte contre les cancers

Care guidelines for cancer survivors often unclear [Reuters]

6.1 Observation

Radiotherapy risks are much higher for smokers [Cancer Research UK]

6.10.1 Politiques (USA)

Trump’s proposed 2018 budget launches a surprise attack on NIH [The Cancer Letter]

6.6 Publications

What leads to bias in the scientific literature? New study tries to answer [Retraction Watch]

6.9 Controverses

Paul Glasziou and Iain Chalmers: Ill informed replications will increase our avoidable waste of research [BMJ Blogs]